1-Chloro-4-(β-D-glucopyranos-1-yl)-2-[4-(pyridin-3-yloxy)-benzyl]-benzene

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-Chloro-4-(β-D-glucopyranos-1-yl)-2-[4-(pyridin-3-yloxy)-benzyl]-benzene
• 英文别名: (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-pyridin-3-yloxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
• 化学式: C₂₄H₂₄ClNO₆
• 分子量: 457.911
• InChiKey: AQZSKFRNWUXTAX-SJSRKZJXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  112
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  3-碘吡啶 、 依帕列净杂质 在 copper(l) iodide 、 2,2,6,6-四甲基-3,5-庚二酮 、 caesium carbonate 作用下， 以 N-甲基吡咯烷酮 为溶剂， 以14%的产率得到1-Chloro-4-(β-D-glucopyranos-1-yl)-2-[4-(pyridin-3-yloxy)-benzyl]-benzene
  参考文献：
  名称：

  Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture

  摘要：

  通式I的葡萄糖吡喃氧基取代的（杂环氧基苄基）-苯化合物，其中基团R1至R6以及R7a、R7b、R7c根据权利要求1定义，包括其互变异构体、立体异构体、混合物及其盐。本发明的化合物适用于治疗代谢性疾病。

  公开号：

  US20060234953A1

文献信息

• Methods for preventing and treating neurodegenerative disorders
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2382972A1

  公开（公告）日：2011-11-02

  The present invention relates to a method for treating, preventing or slowing, delaying or reversing progression of one or more neurodegenerative disorders in a patient in need thereof characterized by administering a glucopyranosyl-substituted benzene derivative, a tautomer, stereoisomer, mixture or salt thereof, as defined in claim 1 to the patient in need thereof.

  本发明涉及一种治疗、预防或减缓、延迟或逆转有需要的患者的一种或多种神经退行性疾病进展的方法，其特征在于向有需要的患者施用权利要求1中定义的葡萄糖吡喃糖基取代的苯衍生物、其同分异构体、立体异构体、混合物或盐。
• GLUCOPYRANOSYL-SUBSTITUTED (HETEROARYLOXY-BENZYL)-BENZENE DERIVATIVES AS SGLT INHIBITORS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP1874787B1

  公开（公告）日：2009-12-30
• METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISORDERS
  申请人：Wienrich Marion

  公开号：US20100081625A1

  公开（公告）日：2010-04-01

  The present invention relates to a method for treating, preventing or slowing, delaying or reversing progression of one or more neurodegenerative disorders in a patient in need thereof characterized by administering a glucopyranosyl-substituted benzene derivative, a tautomer, stereoisomer, mixture or salt thereof, as defined in claim 1 to the patient in need thereof.
• US7662790B2
  申请人：——

  公开号：US7662790B2

  公开（公告）日：2010-02-16
• Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
  申请人：Himmelsbach Frank

  公开号：US20060234953A1

  公开（公告）日：2006-10-19

  Glucopyranosyloxy-substituted (heteroaryloxy-benzyl)-benzene compounds of the general formula I where the groups R 1 to R 6 as well as R 7a , R 7b , R 7c are defined according to claim 1, including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders.

  通式I的葡萄糖吡喃氧基取代的（杂环氧基苄基）-苯化合物，其中基团R1至R6以及R7a、R7b、R7c根据权利要求1定义，包括其互变异构体、立体异构体、混合物及其盐。本发明的化合物适用于治疗代谢性疾病。